Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cAd3-EBO Z + MVA-BN Filo
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intramuscular
01
Overview
cAd3-EBO Z + MVA-BN Filo is a heterologous prime-boost vaccine regimen developed for the prevention of Ebola virus disease and other filovirus infections. The regimen consists of a primary dose of **cAd3-EBO Z** (a monovalent chimpanzee adenovirus type 3 vector expressing the Zaire Ebola virus glycoprotein) followed by a booster dose of **MVA-BN Filo** (a multivalent Modified Vaccinia Ankara vector expressing glycoproteins from Zaire Ebola, Sudan Ebola, and Marburg viruses, along with the Tai Forest virus nucleoprotein). This combination is designed to induce both rapid and durable humoral and cellular immune responses. The **University of Maryland, Baltimore**, served as the lead sponsor for Phase 1b clinical trials in Mali to evaluate the safety and immunogenicity of this regimen in healthy adults. The individual components were developed through collaborations involving the **NIAID Vaccine Research Center**, **GSK**, **Bavarian Nordic**, and **Janssen**.
- Other names
- cAd3-EBO Z/MVA-BN Filo regimenChimpanzee Adenovirus Vector Vaccine + MVA-BN Filo
02
Targets
Zaire ebolavirus glycoproteinPYG (Glycogen phosphorylase)NP (Taï Forest ebolavirus nucleoprotein)
Beyond the preview
Go deeper on cAd3-EBO Z + MVA-BN Filo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cAd3-EBO Z + MVA-BN Filo.